Renal Cell Carcinoma Vaccine Fails to Improve Outcomes
The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.
Temsirolimus/Bevacizumab Not Superior to Standard Treatment With Interferon/Bevacizumab in mRCC
The combination of temsirolimus plus bevacizumab was not superior to interferon plus bevacizumab as first-line therapy for patients with clear cell metastatic renal cell carcinoma.
Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma
Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.
Amrubicin May Be Better Than Topotecan for Second-Line Therapy of Small Cell Lung Cancer
Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.
ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL
Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia
2 Clarke Drive Cranbury, NJ 08512